Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Total Current Liabilities: 2023-2024

Historic Total Current Liabilities for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to $40.7 million.

  • Inhibrx Biosciences' Total Current Liabilities fell 18.40% to $36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.0 million, marking a year-over-year decrease of 18.40%. This contributed to the annual value of $40.7 million for FY2024, which is 27.67% down from last year.
  • Inhibrx Biosciences' Total Current Liabilities amounted to $40.7 million in FY2024, which was down 27.67% from $56.3 million recorded in FY2023.
  • Inhibrx Biosciences' Total Current Liabilities' 5-year high stood at $56.3 million during FY2023, with a 5-year trough of $40.7 million in FY2024.
  • Its 2-year average for Total Current Liabilities is $48.5 million, with a median of $48.5 million in 2023.
  • Data for Inhibrx Biosciences' Total Current Liabilities shows a maximum YoY declined of 27.67% (in 2024) over the last 5 years.
  • Over the past 2 years, Inhibrx Biosciences' Total Current Liabilities (Yearly) stood at $56.3 million in 2023, then dropped by 27.67% to $40.7 million in 2024.